High-frequency irreversible electroporation synergizes with PD-1/PD-L1 inhibitor BMS-1 and TLR7/8 agonist R848 to potentiate liver cancer antitumor immunity

doi:10.3748/wjg.v32.i15.115226

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 32, Issue 15

This Article

(29)

(37)

(0)

(1)

(672)

(1)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastroenterol. Apr 21, 2026; 32(15): 115226
Published online Apr 21, 2026. doi: 10.3748/wjg.v32.i15.115226

Full Size Figure Download Figure

Figure 1 High-frequency irreversible electroporation induces immunogenic cell death in subcutaneous tumor cells. A and B: Immunofluorescence images of key immunogenic cell death markers (high mobility group box 1 protein/calreticulin) in tumors (DAPI for nuclear counterstaining); C and D: Quantitative analysis of their mean fluorescence intensity (n = 8). ^dP < 0.0001. H-FIRE: High-frequency irreversible electroporation; HMGB1: High mobility group box 1 protein; CRT: Calreticulin; MFI: Mean fluorescence intensity.

Citation: Huang SM, Zhang XB, Li J, Zhang GH, Zhang X, Wei YT, Sun H, Ma L, Wang ZJ, Yao DX, Shi HJ, Wang T, Xiao YY. High-frequency irreversible electroporation synergizes with PD-1/PD-L1 inhibitor BMS-1 and TLR7/8 agonist R848 to potentiate liver cancer antitumor immunity. World J Gastroenterol 2026; 32(15): 115226
URL: https://www.wjgnet.com/1007-9327/full/v32/i15/115226.htm
DOI: https://dx.doi.org/10.3748/wjg.v32.i15.115226

Huang SM, Zhang XB, Li J, Zhang GH, Zhang X, Wei YT, Sun H, Ma L, Wang ZJ, Yao DX, Shi HJ, Wang T, Xiao YY. High-frequency irreversible electroporation synergizes with PD-1/PD-L1 inhibitor BMS-1 and TLR7/8 agonist R848 to potentiate liver cancer antitumor immunity. World J Gastroenterol 2026; 32(15): 115226 [DOI: 10.3748/wjg.v32.i15.115226]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.